Mendelian Secures £1.4M Funding for AI Health Innovation
Mendelian, a pioneering digital health company based in London, UK, has recently achieved a significant milestone by securing over £1.4 million in funding. This funding comes from the prestigious Artificial Intelligence in Health and Care Awards (AI Awards), which is orchestrated by the NHS AI Lab in collaboration with the National Institute for Health and Care Research (NIHR) and the Accelerated Access Collaborative (AAC). This accolade not only underscores the innovative work being done by Mendelian but also reflects the growing recognition of the crucial role that artificial intelligence can play in enhancing healthcare delivery, particularly for patients with rare diseases.
Under the leadership of Chief Executive Officer Dr.
Peter Fish, Mendelian has created the MendelScan software, a cutting-edge AI case-finding tool designed to expedite the identification and diagnosis of patients suffering from undiagnosed or unrecognized rare diseases. Currently, this software is implemented in over 50 National Health Service (NHS) primary care practices throughout England. The initiative aims to optimize patient pathways, helping healthcare providers transition patients towards possible diagnoses more efficiently. This is particularly significant given that rare diseases often go undiagnosed for extended periods, causing delays in treatment and negatively impacting patient outcomes.
The recent funding award serves as a catalyst for Mendelian's expansion plans. The company intends to utilize these resources to further develop and enhance its MendelScan solution, trialing it within primary care electronic health records across GP practices in the UK. In addition to refining the existing software, the focus will also be on conducting real-world efficacy testing. This will allow Mendelian to gather robust evidence of the software's effectiveness, paving the way for the potential nationwide adoption of this transformative tool across the entire health service. Such advancements could revolutionize the diagnosis process for rare diseases, offering hope to countless patients and their families.
They've invested in Mendelian
Get to know these Healthtech investors
Click here for a full list of 7,526+ startup investors in the UK